Metastatic Colorectal Cancer Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos

“Metastatic Colorectal Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Colorectal Cancer Market.

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Colorectal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Colorectal Cancer treatment therapies with a considerable amount of success over the years.

• Metastatic Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceutical, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmaceuti cals Co., Ltd, Amgen, G1 Therapeutic s, Inc., and others, are developing therapies for the Metastatic Colorectal Cancer treatment

• Emerging Metastatic Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others are expected to have a significant impact on the Metastatic Colorectal Cancer market in the coming years.

• In April 2025, Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotech firm focused on PLK1 inhibition to create innovative cancer treatments, has announced that patient enrollment is now complete for its ongoing Phase 2 CRDF-004 trial. The study is assessing the efficacy of onvansertib in combination with standard-of-care therapy for treating first-line RAS-mutated metastatic colorectal cancer (mCRC).

• In February 2025, Pfizer’s combination therapy for metastatic colorectal cancer (mCRC) achieved one of its primary goals—significantly improving progression-free survival (PFS)—in a Phase III clinical trial, strengthening the case for full regulatory approval. The active-controlled, open-label BREAKWATER study (NCT05217446) assessed a regimen combining Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The therapy was evaluated in previously untreated mCRC patients with a BRAF V600E mutation and successfully met one of its dual primary endpoints by demonstrating improved PFS.

• In November 2024, Tizona Therapeutics has broadened its ongoing Phase Ib clinical trial of TTX-080, a novel antibody targeting human leukocyte antigen-G (HLA-G), to include patients with biomarker-defined metastatic colorectal cancer (mCRC).

• In September 2024, FRUZAQLA® (fruquintinib) is a kinase inhibitor approved for the treatment of adults with metastatic colorectal cancer (mCRC). This innovative oral treatment is designed for once-daily use, providing a non-chemotherapy alternative for patients who have previously received specific anti-cancer therapies. These may include chemotherapy regimens based on fluoropyrimidine, oxaliplatin, and irinotecan, as well as anti-vascular endothelial growth factor (VEGF) therapy.

• In January 2024, Bold Therapeutics, a biopharmaceutical company in the clinical stage, shared favorable results from Phase 2 trials assessing the safety and effectiveness of BOLD-100 in combination with FOLFOX. These trials focused on patients with advanced metastatic colorectal cancer who had previously received treatment with FOLFOX/CAPOX. The findings were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held from January 18 to 20, 2024.

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer refers to a stage of colorectal cancer where cancer cells have spread from the primary site (the colon or rectum) to other parts of the body, forming secondary tumors. Colorectal cancer typically starts as a growth of tissue (polyp) in the lining of the colon or rectum and may progress through various stages, with metastatic or advanced stages indicating a more widespread and severe condition.

Get a Free Sample PDF Report to know more about Metastatic Colorectal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight

Emerging Metastatic Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:

• 188RNL-BAM: Plus Therapeutics

• PCS11T: Processa Pharmaceutic als

• HLX13: Shanghai Henlius Biotech

• Geptanolimab: Genor Biopharma

• HDM201: Novartis Pharmaceutical

• TP-1454: Sumitomo Pharma Oncology

• NT219: Purple Biotech Ltd.

• NKTR-255: Nektar Therapeutics

• Evorpacept (ALX148): ALX Oncology Inc.

• CPGJ 602: Sunshine Guojian Pharmaceutic al

• Trastuzumab deruxtecan: Daiichi Sanky

• GRT-C901: Gritstone Bio, Inc

• SHR-1701: Suzhou Suncadia Biopharmaceuti cals Co., Ltd

• Lumakras (sotorasib): Amgen

• Trilaciclib: G1 Therapeutic s, Inc.

Metastatic Colorectal Cancer Route of Administration

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Metastatic Colorectal Cancer Molecule Type

Metastatic Colorectal Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

• Metastatic Colorectal Cancer Assessment by Product Type

• Metastatic Colorectal Cancer By Stage and Product Type

• Metastatic Colorectal Cancer Assessment by Route of Administration

• Metastatic Colorectal Cancer By Stage and Route of Administration

• Metastatic Colorectal Cancer Assessment by Molecule Type

• Metastatic Colorectal Cancer by Stage and Molecule Type

DelveInsight’s Metastatic Colorectal Cancer Report covers around 180+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Metastatic Colorectal Cancer product details are provided in the report. Download the Metastatic Colorectal Cancer pipeline report to learn more about the emerging Metastatic Colorectal Cancer therapies

Some of the key companies in the Metastatic Colorectal Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Colorectal Cancer are – Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, and others.

Metastatic Colorectal Cancer Pipeline Analysis:

The Metastatic Colorectal Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.

• Metastatic Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Colorectal Cancer drugs and therapies

Metastatic Colorectal Cancer Pipeline Market Drivers

• Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Metastatic Colorectal Cancer Market.

Metastatic Colorectal Cancer Pipeline Market Barriers

• However, limitations in understanding secondary resistance, challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Metastatic Colorectal Cancer Market growth.

Scope of Metastatic Colorectal Cancer Pipeline Drug Insight

• Coverage: Global

• Key Metastatic Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceutical, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmaceuti cals Co., Ltd, Amgen, G1 Therapeutic s, Inc., and others

• Key Metastatic Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others

• Metastatic Colorectal Cancer Therapeutic Assessment: Metastatic Colorectal Cancer current marketed and Metastatic Colorectal Cancer emerging therapies

• Metastatic Colorectal Cancer Market Dynamics: Metastatic Colorectal Cancer market drivers and Metastatic Colorectal Cancer market barriers

Request for Sample PDF Report for Metastatic Colorectal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Colorectal Cancer Report Introduction

2. Metastatic Colorectal Cancer Executive Summary

3. Metastatic Colorectal Cancer Overview

4. Metastatic Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Colorectal Cancer Pipeline Therapeutics

6. Metastatic Colorectal Cancer Late Stage Products (Phase II/III)

7. Metastatic Colorectal Cancer Mid Stage Products (Phase II)

8. Metastatic Colorectal Cancer Early Stage Products (Phase I)

9. Metastatic Colorectal Cancer Preclinical Stage Products

10. Metastatic Colorectal Cancer Therapeutics Assessment

11. Metastatic Colorectal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Colorectal Cancer Key Companies

14. Metastatic Colorectal Cancer Key Products

15. Metastatic Colorectal Cancer Unmet Needs

16 . Metastatic Colorectal Cancer Market Drivers and Barriers

17. Metastatic Colorectal Cancer Future Perspectives and Conclusion

18. Metastatic Colorectal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/